Drug Profile
SR 4980
Alternative Names: CDB 3146Latest Information Update: 19 May 1998
Price :
$50
*
At a glance
- Originator SRI International
- Class Antiandrogens; Antineoplastics; Hormones
- Mechanism of Action Testosterone congener inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Prostate cancer
Most Recent Events
- 19 May 1998 No-Development-Reported for Prostate cancer in USA (Unknown route)
- 25 Sep 1996 New profile
- 25 Sep 1996 Preclinical development for Prostate cancer in USA (Unknown route)